188 related articles for article (PubMed ID: 27373506)
21. Afatinib and lung cancer.
Jain P; Khanal R; Sharma A; Yan F; Sharma N
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1391-406. PubMed ID: 25417728
[TBL] [Abstract][Full Text] [Related]
22. HER2 activating mutations are targets for colorectal cancer treatment.
Kavuri SM; Jain N; Galimi F; Cottino F; Leto SM; Migliardi G; Searleman AC; Shen W; Monsey J; Trusolino L; Jacobs SA; Bertotti A; Bose R
Cancer Discov; 2015 Aug; 5(8):832-41. PubMed ID: 26243863
[TBL] [Abstract][Full Text] [Related]
23. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
24. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
[TBL] [Abstract][Full Text] [Related]
25. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
26. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma.
Mao X; Chen Z; Zhao Y; Yu Y; Guan S; Woodfield SE; Vasudevan SA; Tao L; Pang JC; Lu J; Zhang H; Zhang F; Yang J
Oncotarget; 2017 Jan; 8(1):1555-1568. PubMed ID: 27902463
[TBL] [Abstract][Full Text] [Related]
27. Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Pauwels P; Peeters M; Vermorken JB; Wouters A
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30650638
[TBL] [Abstract][Full Text] [Related]
28. Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling.
Watanuki Z; Kosai H; Osanai N; Ogama N; Mochizuki M; Tamai K; Yamaguchi K; Satoh K; Fukuhara T; Maemondo M; Ichinose M; Nukiwa T; Tanaka N
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):269-76. PubMed ID: 25446083
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?
Damjanov N; Meropol NJ
Oncology (Williston Park); 2004 Apr; 18(4):479-88; discussion 488, 493, 497 passim. PubMed ID: 15134356
[TBL] [Abstract][Full Text] [Related]
30. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
32. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.
Liao BC; Lin CC; Yang JC
Curr Oncol Rep; 2017 Jan; 19(1):4. PubMed ID: 28138934
[TBL] [Abstract][Full Text] [Related]
33. [Afatinib (BIBW 2992)].
Prim N; Fore M; Mennecier B
Rev Pneumol Clin; 2014 Oct; 70(5):279-85. PubMed ID: 24878189
[TBL] [Abstract][Full Text] [Related]
34. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
[TBL] [Abstract][Full Text] [Related]
35. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
Yang JC; Shih JY; Su WC; Hsia TC; Tsai CM; Ou SH; Yu CJ; Chang GC; Ho CL; Sequist LV; Dudek AZ; Shahidi M; Cong XJ; Lorence RM; Yang PC; Miller VA
Lancet Oncol; 2012 May; 13(5):539-48. PubMed ID: 22452895
[TBL] [Abstract][Full Text] [Related]
36. Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
Kuo T; Fisher GA
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S62-70. PubMed ID: 16336751
[TBL] [Abstract][Full Text] [Related]
37. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
Tsai YC; Yeh CH; Tzen KY; Ho PY; Tuan TF; Pu YS; Cheng AL; Cheng JC
Eur J Cancer; 2013 Apr; 49(6):1458-66. PubMed ID: 23153706
[TBL] [Abstract][Full Text] [Related]
38. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
Giordano P; Manzo A; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Daniele G; Normanno N; Carillio G; Rocco G; Bianco R; Perrone F; Morabito A
Crit Rev Oncol Hematol; 2016 Jan; 97():143-51. PubMed ID: 26318094
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
Xue C; Tian Y; Zhang J; Zhao Y; Zhan J; Fang W; Zhang L
Drug Des Devel Ther; 2016; 10():1299-306. PubMed ID: 27099475
[TBL] [Abstract][Full Text] [Related]
40. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
Solca F; Dahl G; Zoephel A; Bader G; Sanderson M; Klein C; Kraemer O; Himmelsbach F; Haaksma E; Adolf GR
J Pharmacol Exp Ther; 2012 Nov; 343(2):342-50. PubMed ID: 22888144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]